tiprankstipranks
Trending News
More News >
Silence Therapeutics (SLN)
NASDAQ:SLN
US Market

Silence Therapeutics (SLN) Stock Forecast & Price Target

Compare
158 Followers
See the Price Targets and Ratings of:

SLN Analyst Ratings

Moderate Buy
7Ratings
6 Buy
0 Hold
1 Sell
Based on 7 analysts giving stock ratings to
Silence
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SLN Stock 12 Month Forecast

Average Price Target

$32.33
▲(639.82% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Silence Therapeutics in the last 3 months. The average price target is $32.33 with a high forecast of $75.00 and a low forecast of $4.00. The average price target represents a 639.82% change from the last price of $4.37.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","76":"$76","21.25":"$21.3","39.5":"$39.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,21.25,39.5,57.75,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.01,9.47076923076923,14.93153846153846,20.39230769230769,25.85307692307692,31.31384615384615,36.77461538461538,42.23538461538461,47.69615384615384,53.15692307692307,58.6176923076923,64.07846153846154,69.53923076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.01,6.188461538461539,8.366923076923076,10.545384615384615,12.723846153846154,14.902307692307692,17.080769230769228,19.25923076923077,21.43769230769231,23.616153846153843,25.794615384615383,27.973076923076924,30.151538461538458,{"y":32.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.01,4.009230769230769,4.008461538461538,4.007692307692308,4.006923076923076,4.006153846153846,4.0053846153846155,4.004615384615384,4.003846153846154,4.003076923076923,4.002307692307692,4.001538461538462,4.00076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.78,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.99,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.74,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.79,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$75.00Average Price Target$32.33Lowest Price Target$4.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on SLN
Keay NakaeChardan Capital
Chardan Capital
$35
Buy
700.92%
Upside
Reiterated
05/09/25
H.C. Wainwright Analyst forecast on SLN
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$75
Buy
1616.25%
Upside
Reiterated
05/09/25
Morgan Stanley Analyst forecast on SLN
Michael UlzMorgan Stanley
Morgan Stanley
$45$25
Buy
472.08%
Upside
Reiterated
05/09/25
William Blair Analyst forecast on SLN
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/08/25
Goldman Sachs Analyst forecast on SLN
Richard Law CFAGoldman Sachs
Goldman Sachs
$6$4
Sell
-8.47%
Downside
Reiterated
03/04/25
BMO Capital Analyst forecast on SLN
Kostas BiliourisBMO Capital
BMO Capital
$67$25
Buy
472.08%
Upside
Reiterated
03/04/25
Jefferies Analyst forecast on SLN
Kelly ShiJefferies
Jefferies
$31$30
Buy
586.50%
Upside
Reiterated
02/27/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Chardan Capital Analyst forecast on SLN
Keay NakaeChardan Capital
Chardan Capital
$35
Buy
700.92%
Upside
Reiterated
05/09/25
H.C. Wainwright Analyst forecast on SLN
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$75
Buy
1616.25%
Upside
Reiterated
05/09/25
Morgan Stanley Analyst forecast on SLN
Michael UlzMorgan Stanley
Morgan Stanley
$45$25
Buy
472.08%
Upside
Reiterated
05/09/25
William Blair Analyst forecast on SLN
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/08/25
Goldman Sachs Analyst forecast on SLN
Richard Law CFAGoldman Sachs
Goldman Sachs
$6$4
Sell
-8.47%
Downside
Reiterated
03/04/25
BMO Capital Analyst forecast on SLN
Kostas BiliourisBMO Capital
BMO Capital
$67$25
Buy
472.08%
Upside
Reiterated
03/04/25
Jefferies Analyst forecast on SLN
Kelly ShiJefferies
Jefferies
$31$30
Buy
586.50%
Upside
Reiterated
02/27/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Silence Therapeutics

Which Analyst Should I Follow If I Want to Buy SLN and Sell After:
1 Month
xxx
Success Rate
8/12 ratings generated profit
67%
Average Return
+5.64%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.64% per trade.
3 Months
xxx
Success Rate
8/12 ratings generated profit
67%
Average Return
+13.14%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +13.14% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
5/12 ratings generated profit
42%
Average Return
-12.07%
reiterated a buy rating 12 days ago
Copying Myles Minter's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of -12.07% per trade.
2 Years
xxx
Success Rate
3/12 ratings generated profit
25%
Average Return
-45.89%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -45.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLN Analyst Recommendation Trends

Rating
Dec 24
Jan 25
Feb 25
Mar 25
May 25
Strong Buy
13
12
8
7
9
Buy
0
0
1
1
2
Hold
0
0
0
0
0
Sell
0
0
1
2
2
Strong Sell
0
0
0
0
0
total
13
12
10
10
13
In the current month, SLN has received 11 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. SLN average Analyst price target in the past 3 months is 32.33.
Each month's total comprises the sum of three months' worth of ratings.

SLN Financial Forecast

SLN Earnings Forecast

Next quarter’s earnings estimate for SLN is -$0.18 with a range of -$0.43 to -$0.09. The previous quarter’s EPS was -$0.20. SLN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.26% of the time in the same period. In the last calendar year SLN has Outperformed its overall industry.
Next quarter’s earnings estimate for SLN is -$0.18 with a range of -$0.43 to -$0.09. The previous quarter’s EPS was -$0.20. SLN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.26% of the time in the same period. In the last calendar year SLN has Outperformed its overall industry.

SLN Sales Forecast

Next quarter’s sales forecast for SLN is $6.16M with a range of $134.92K to $14.69M. The previous quarter’s sales results were $142.55K. SLN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year SLN has Preformed in-line its overall industry.
Next quarter’s sales forecast for SLN is $6.16M with a range of $134.92K to $14.69M. The previous quarter’s sales results were $142.55K. SLN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year SLN has Preformed in-line its overall industry.

SLN Stock Forecast FAQ

What is SLN’s average 12-month price target, according to analysts?
Based on analyst ratings, Silence Therapeutics’s 12-month average price target is 32.33.
    What is SLN’s upside potential, based on the analysts’ average price target?
    Silence Therapeutics has 639.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SLN a Buy, Sell or Hold?
          Silence Therapeutics has a consensus rating of Moderate Buy which is based on 6 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Silence Therapeutics’s price target?
            The average price target for Silence Therapeutics is 32.33. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $75.00 ,the lowest forecast is $4.00. The average price target represents 639.82% Increase from the current price of $4.37.
              What do analysts say about Silence Therapeutics?
              Silence Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of SLN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis